Cosmetic cross-reference

Valine

CAS 72-18-4

Valine (CAS 72-18-4) is a Phase 2 pharmaceutical compound with 1 bioactivity target and 2 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
3
SOURCE DrugCentral
Adverse signals
2
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Valine
CAS Number
72-18-4
UNII
HG18B9YRS7
InChIKey
KZSNJWFQEVHDMF-BYPYZUCNSA-N
ChEMBL ID
CHEMBL43068
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
L-valine
natural product
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 2
Mid-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL43068 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE EMBL-EBI ChEMBL 3 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- MIC 6130.7692307692305 nM 13 -
- IC50 68000 nM 1 -
Large neutral amino acids transporter small subunit 1
Transporter
IC50 4.17 - Homo sapiens
SOURCE DrugCentral 2 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Foetal growth restriction 15 64.586 10070531
Compartment syndrome 10 49.22 10010121

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 4 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
Valine 11115 SU MTHSPL
VALINE 11115 SU MTHSPL
valine 11115 IN RXNORM
L-valine 11115 SY RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Valine used for in pharmaceutical contexts?

Valine (CAS 72-18-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Valine?

Valine has 2 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Foetal growth restriction, Compartment syndrome. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Valine also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for L-Valine with EU status "permitted".

What clinical phase is Valine in?

Valine is rendered with ChEMBL max phase 2.

What bioactivity targets are documented for Valine?

Valine has 3 bioactivity rows in this page query. Rendered target entries include Large neutral amino acids transporter small subunit 1.